Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in EUR (TTM)69.29m
- Net income in EUR-29.68m
- Incorporated2000
- Employees224.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttps://www.cellectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurofins Cerep SA | 40.46m | 7.15m | 81.21m | 207.00 | 11.35 | 1.13 | 8.49 | 2.01 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Ose Immunotherapeutics SA | 2.22m | -34.84m | 99.74m | 68.00 | -- | 1.97 | -- | 44.95 | -1.59 | -1.59 | 0.1009 | 2.26 | 0.0181 | -- | 0.4821 | 34,671.88 | -28.42 | -7.66 | -33.45 | -9.27 | -- | -- | -1,569.85 | -26.10 | -- | -- | 0.4331 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Abionyx Pharma SA | 4.33m | -4.60m | 128.73m | 51.00 | -- | 22.91 | -- | 29.76 | -0.1317 | -0.1317 | 0.1238 | 0.1582 | 0.3033 | 17.39 | 7.16 | 84,823.53 | -32.25 | -26.53 | -43.11 | -38.31 | 17.78 | 15.59 | -106.31 | -131.06 | 1.35 | -- | 0.4281 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Adocia SA | 10.35m | -9.71m | 129.80m | 77.00 | -- | -- | -- | 12.54 | -0.5622 | -0.5622 | 0.6343 | -0.0338 | 0.4068 | -- | 2.55 | 134,428.60 | -38.16 | -47.62 | -184.08 | -104.50 | -- | -- | -93.83 | -331.17 | 1.12 | -14.58 | 1.06 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| Innate Pharma SA | 6.00m | -46.05m | 131.42m | 181.00 | -- | 25.12 | -- | 21.90 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Maat Pharma SA | 3.92m | -31.13m | 133.27m | 60.00 | -- | 13.77 | -- | 33.98 | -2.15 | -2.15 | 0.270 | 0.5141 | 0.0786 | 11.22 | 0.5785 | 65,366.67 | -62.39 | -41.51 | -90.20 | -51.87 | 61.68 | -- | -793.83 | -976.99 | 2.21 | -29.53 | 0.6346 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Sensorion SA | 0.00 | -28.09m | 167.87m | 68.00 | -- | 1.72 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Cellectis SA | 69.29m | -29.68m | 228.11m | 224.00 | -- | 2.71 | -- | 3.29 | -0.2959 | -0.2959 | 0.6889 | 1.17 | 0.2234 | -- | 8.58 | 309,352.50 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Transgene SA | 7.24m | -36.78m | 232.51m | 147.00 | -- | -- | -- | 32.12 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Eurobio Scientific SA | 162.09m | 2.36m | 244.95m | 380.00 | 101.88 | 1.33 | 13.75 | 1.51 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Genfit SA | 45.41m | -38.76m | 312.73m | 188.00 | -- | 5.96 | -- | 6.89 | -0.7737 | -0.7737 | 0.9083 | 1.05 | 0.2207 | 519.75 | 0.9236 | 252,277.80 | -18.84 | -7.73 | -23.25 | -9.79 | 95.42 | 95.68 | -85.35 | -37.15 | 3.74 | -10.87 | 0.1223 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Valneva SE | 179.91m | -102.16m | 709.52m | 700.00 | -- | 4.70 | -- | 3.94 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Nanobiotix SA | -14.04m | -51.64m | 937.05m | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
Data as of Feb 10 2026. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR
2.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CDC Croissance SAas of 15 Feb 2025 | 1.04m | 1.44% |
| Montpensier Arbevel SASas of 31 Dec 2024 | 300.34k | 0.42% |
| OFI Invest Asset Management SAas of 29 Jan 2026 | 200.00k | 0.28% |
| Saint Olive Gestion SNCas of 30 Jun 2025 | 85.00k | 0.12% |
| Perinvest (UK) Ltd.as of 29 Sep 2023 | 10.29k | 0.01% |
| State Street Global Advisors Europe Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
| KBC Asset Management NVas of 31 Dec 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
